nodes	percent_of_prediction	percent_of_DWPC	metapath
Lomefloxacin—ABCC2—esophageal cancer	0.607	1	CbGaD
Lomefloxacin—ABCC2—Carboplatin—esophageal cancer	0.11	0.415	CbGbCtD
Lomefloxacin—ABCC2—Cisplatin—esophageal cancer	0.0939	0.355	CbGbCtD
Lomefloxacin—ABCC2—Methotrexate—esophageal cancer	0.0609	0.23	CbGbCtD
Lomefloxacin—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00157	0.0355	CbGpPWpGaD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT14—esophageal cancer	0.00144	0.0325	CbGpPWpGaD
Lomefloxacin—ABCC2—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00136	0.0307	CbGpPWpGaD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—RUNX1—esophageal cancer	0.00117	0.0265	CbGpPWpGaD
Lomefloxacin—Sparfloxacin—ABCC2—esophageal cancer	0.00102	0.318	CrCbGaD
Lomefloxacin—Intestinal perforation—Methotrexate—esophageal cancer	0.00094	0.0117	CcSEcCtD
Lomefloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000904	0.0204	CbGpPWpGaD
Lomefloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000904	0.0204	CbGpPWpGaD
Lomefloxacin—CYP1A2—Sulindac Metabolic Pathway—CYP1B1—esophageal cancer	0.000903	0.0204	CbGpPWpGaD
Lomefloxacin—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.000839	0.0104	CcSEcCtD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—SFN—esophageal cancer	0.0008	0.0181	CbGpPWpGaD
Lomefloxacin—Aphasia—Capecitabine—esophageal cancer	0.00077	0.00957	CcSEcCtD
Lomefloxacin—CYP1A2—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.000761	0.0172	CbGpPWpGaD
Lomefloxacin—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.000744	0.0168	CbGpPWpGaD
Lomefloxacin—Ofloxacin—ABCC2—esophageal cancer	0.000715	0.224	CrCbGaD
Lomefloxacin—Torsade de pointes—Capecitabine—esophageal cancer	0.000712	0.00885	CcSEcCtD
Lomefloxacin—Metrorrhagia—Capecitabine—esophageal cancer	0.000699	0.00869	CcSEcCtD
Lomefloxacin—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.000687	0.0155	CbGpPWpGaD
Lomefloxacin—Hiccups—Cisplatin—esophageal cancer	0.000677	0.00842	CcSEcCtD
Lomefloxacin—ABCC2—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000676	0.0153	CbGpPWpGaD
Lomefloxacin—CYP1A2—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.000669	0.0151	CbGpPWpGaD
Lomefloxacin—CYP1A2—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.000667	0.0151	CbGpPWpGaD
Lomefloxacin—Skin exfoliation—Cisplatin—esophageal cancer	0.000646	0.00804	CcSEcCtD
Lomefloxacin—Fungal infection—Capecitabine—esophageal cancer	0.000646	0.00804	CcSEcCtD
Lomefloxacin—Skin ulcer—Capecitabine—esophageal cancer	0.000641	0.00797	CcSEcCtD
Lomefloxacin—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.000629	0.0142	CbGpPWpGaD
Lomefloxacin—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.000625	0.00777	CcSEcCtD
Lomefloxacin—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.00062	0.014	CbGpPWpGaD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—esophageal cancer	0.000616	0.0139	CbGpPWpGaD
Lomefloxacin—Vaginal discharge—Methotrexate—esophageal cancer	0.000611	0.00759	CcSEcCtD
Lomefloxacin—Extrasystoles—Capecitabine—esophageal cancer	0.000593	0.00738	CcSEcCtD
Lomefloxacin—Aphasia—Methotrexate—esophageal cancer	0.000573	0.00712	CcSEcCtD
Lomefloxacin—Norfloxacin—CYP2A6—esophageal cancer	0.000573	0.179	CrCbGaD
Lomefloxacin—Phlebitis—Cisplatin—esophageal cancer	0.000571	0.00709	CcSEcCtD
Lomefloxacin—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.000564	0.0127	CbGpPWpGaD
Lomefloxacin—Polyuria—Cisplatin—esophageal cancer	0.00056	0.00696	CcSEcCtD
Lomefloxacin—Skin discolouration—Capecitabine—esophageal cancer	0.000553	0.00687	CcSEcCtD
Lomefloxacin—Haemolytic anaemia—Cisplatin—esophageal cancer	0.000544	0.00677	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—ALDH3A1—esophageal cancer	0.000536	0.0121	CbGpPWpGaD
Lomefloxacin—Cyanosis—Methotrexate—esophageal cancer	0.000525	0.00653	CcSEcCtD
Lomefloxacin—TOP2A—Gastric Cancer Network 1—NOTCH1—esophageal cancer	0.000511	0.0115	CbGpPWpGaD
Lomefloxacin—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000508	0.00631	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—ALDH3A1—esophageal cancer	0.000507	0.0115	CbGpPWpGaD
Lomefloxacin—Hiccups—Capecitabine—esophageal cancer	0.000499	0.00621	CcSEcCtD
Lomefloxacin—Pulmonary embolism—Capecitabine—esophageal cancer	0.000499	0.00621	CcSEcCtD
Lomefloxacin—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000492	0.00611	CcSEcCtD
Lomefloxacin—Influenza like illness—Capecitabine—esophageal cancer	0.000485	0.00603	CcSEcCtD
Lomefloxacin—Fungal infection—Methotrexate—esophageal cancer	0.000481	0.00598	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—BLVRB—esophageal cancer	0.000478	0.0108	CbGpPWpGaD
Lomefloxacin—Skin ulcer—Methotrexate—esophageal cancer	0.000477	0.00593	CcSEcCtD
Lomefloxacin—Skin exfoliation—Capecitabine—esophageal cancer	0.000477	0.00593	CcSEcCtD
Lomefloxacin—Candida infection—Capecitabine—esophageal cancer	0.000477	0.00593	CcSEcCtD
Lomefloxacin—Face oedema—Cisplatin—esophageal cancer	0.000475	0.0059	CcSEcCtD
Lomefloxacin—CYP1A2—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00047	0.0106	CbGpPWpGaD
Lomefloxacin—Blood creatinine increased—Cisplatin—esophageal cancer	0.00046	0.00573	CcSEcCtD
Lomefloxacin—Urine output increased—Capecitabine—esophageal cancer	0.000451	0.00561	CcSEcCtD
Lomefloxacin—TOP2A—Circadian rythm related genes—CRTC1—esophageal cancer	0.000449	0.0102	CbGpPWpGaD
Lomefloxacin—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000449	0.0101	CbGpPWpGaD
Lomefloxacin—CYP1A2—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.000442	0.00998	CbGpPWpGaD
Lomefloxacin—Abnormal vision—Capecitabine—esophageal cancer	0.000435	0.00541	CcSEcCtD
Lomefloxacin—Mental disability—Capecitabine—esophageal cancer	0.000433	0.00539	CcSEcCtD
Lomefloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000428	0.00966	CbGpPWpGaD
Lomefloxacin—Ear pain—Capecitabine—esophageal cancer	0.000425	0.00528	CcSEcCtD
Lomefloxacin—Phlebitis—Capecitabine—esophageal cancer	0.000421	0.00523	CcSEcCtD
Lomefloxacin—CYP1A2—Estrogen Receptor Pathway—CYP1B1—esophageal cancer	0.000421	0.0095	CbGpPWpGaD
Lomefloxacin—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000415	0.00515	CcSEcCtD
Lomefloxacin—Sweating increased—Cisplatin—esophageal cancer	0.000414	0.00515	CcSEcCtD
Lomefloxacin—Polyuria—Capecitabine—esophageal cancer	0.000413	0.00513	CcSEcCtD
Lomefloxacin—Photosensitivity—Capecitabine—esophageal cancer	0.000413	0.00513	CcSEcCtD
Lomefloxacin—Skin discolouration—Methotrexate—esophageal cancer	0.000411	0.00511	CcSEcCtD
Lomefloxacin—ABCC2—ABC-family proteins mediated transport—ABCB1—esophageal cancer	0.000408	0.00922	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000407	0.0092	CbGpPWpGaD
Lomefloxacin—ABCC2—NRF2 pathway—PRDX1—esophageal cancer	0.000406	0.00918	CbGpPWpGaD
Lomefloxacin—Vascular purpura—Capecitabine—esophageal cancer	0.000405	0.00504	CcSEcCtD
Lomefloxacin—Eye pain—Capecitabine—esophageal cancer	0.000401	0.00499	CcSEcCtD
Lomefloxacin—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000401	0.00499	CcSEcCtD
Lomefloxacin—Hot flush—Capecitabine—esophageal cancer	0.000387	0.00482	CcSEcCtD
Lomefloxacin—Increased appetite—Capecitabine—esophageal cancer	0.000386	0.00479	CcSEcCtD
Lomefloxacin—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000384	0.00477	CcSEcCtD
Lomefloxacin—Menopausal symptoms—Capecitabine—esophageal cancer	0.000384	0.00477	CcSEcCtD
Lomefloxacin—Thirst—Capecitabine—esophageal cancer	0.000381	0.00473	CcSEcCtD
Lomefloxacin—Vasculitis—Methotrexate—esophageal cancer	0.000381	0.00473	CcSEcCtD
Lomefloxacin—Dermatitis bullous—Capecitabine—esophageal cancer	0.000379	0.00471	CcSEcCtD
Lomefloxacin—Purpura—Capecitabine—esophageal cancer	0.000376	0.00467	CcSEcCtD
Lomefloxacin—Sparfloxacin—ABCB1—esophageal cancer	0.000374	0.117	CrCbGaD
Lomefloxacin—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000373	0.00464	CcSEcCtD
Lomefloxacin—Renal failure—Cisplatin—esophageal cancer	0.000372	0.00463	CcSEcCtD
Lomefloxacin—Vaginal inflammation—Methotrexate—esophageal cancer	0.000372	0.00462	CcSEcCtD
Lomefloxacin—Pulmonary embolism—Methotrexate—esophageal cancer	0.000372	0.00462	CcSEcCtD
Lomefloxacin—Myocardial infarction—Cisplatin—esophageal cancer	0.000371	0.00462	CcSEcCtD
Lomefloxacin—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000371	0.00462	CcSEcCtD
Lomefloxacin—Cardiac failure—Capecitabine—esophageal cancer	0.000371	0.00462	CcSEcCtD
Lomefloxacin—CYP1A2—Xenobiotics—CYP2A6—esophageal cancer	0.00037	0.00835	CbGpPWpGaD
Lomefloxacin—Stomatitis—Cisplatin—esophageal cancer	0.000369	0.00459	CcSEcCtD
Lomefloxacin—Conjunctivitis—Cisplatin—esophageal cancer	0.000368	0.00458	CcSEcCtD
Lomefloxacin—Diplopia—Capecitabine—esophageal cancer	0.000362	0.00451	CcSEcCtD
Lomefloxacin—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000362	0.00451	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—SLC39A6—esophageal cancer	0.000362	0.00818	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—HMGB1—esophageal cancer	0.000359	0.00812	CbGpPWpGaD
Lomefloxacin—CYP1A2—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.000355	0.00803	CbGpPWpGaD
Lomefloxacin—Skin exfoliation—Methotrexate—esophageal cancer	0.000355	0.00441	CcSEcCtD
Lomefloxacin—Vaginal infection—Methotrexate—esophageal cancer	0.000351	0.00436	CcSEcCtD
Lomefloxacin—Face oedema—Capecitabine—esophageal cancer	0.00035	0.00435	CcSEcCtD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—esophageal cancer	0.000347	0.00784	CbGpPWpGaD
Lomefloxacin—Bradycardia—Cisplatin—esophageal cancer	0.000346	0.0043	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—ADH7—esophageal cancer	0.000346	0.00781	CbGpPWpGaD
Lomefloxacin—Urinary retention—Capecitabine—esophageal cancer	0.000345	0.00428	CcSEcCtD
Lomefloxacin—Ataxia—Capecitabine—esophageal cancer	0.000341	0.00424	CcSEcCtD
Lomefloxacin—Coma—Methotrexate—esophageal cancer	0.00034	0.00422	CcSEcCtD
Lomefloxacin—Blood creatinine increased—Capecitabine—esophageal cancer	0.000339	0.00422	CcSEcCtD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000339	0.00766	CbGpPWpGaD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000339	0.00766	CbGpPWpGaD
Lomefloxacin—Urine output increased—Methotrexate—esophageal cancer	0.000336	0.00418	CcSEcCtD
Lomefloxacin—Pulmonary oedema—Methotrexate—esophageal cancer	0.000331	0.00411	CcSEcCtD
Lomefloxacin—Visual impairment—Cisplatin—esophageal cancer	0.000328	0.00407	CcSEcCtD
Lomefloxacin—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000326	0.00406	CcSEcCtD
Lomefloxacin—CYP1A2—Estrogen metabolism—CYP1B1—esophageal cancer	0.000324	0.00732	CbGpPWpGaD
Lomefloxacin—Tinnitus—Cisplatin—esophageal cancer	0.000317	0.00394	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000316	0.00714	CbGpPWpGaD
Lomefloxacin—Lymphadenopathy—Methotrexate—esophageal cancer	0.000316	0.00393	CcSEcCtD
Lomefloxacin—Flushing—Cisplatin—esophageal cancer	0.000316	0.00392	CcSEcCtD
Lomefloxacin—Dysphagia—Capecitabine—esophageal cancer	0.000313	0.00389	CcSEcCtD
Lomefloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000312	0.00705	CbGpPWpGaD
Lomefloxacin—Bronchospasm—Capecitabine—esophageal cancer	0.000308	0.00383	CcSEcCtD
Lomefloxacin—Photosensitivity—Methotrexate—esophageal cancer	0.000307	0.00382	CcSEcCtD
Lomefloxacin—Polyuria—Methotrexate—esophageal cancer	0.000307	0.00382	CcSEcCtD
Lomefloxacin—Sweating increased—Capecitabine—esophageal cancer	0.000305	0.00379	CcSEcCtD
Lomefloxacin—Angina pectoris—Capecitabine—esophageal cancer	0.000305	0.00379	CcSEcCtD
Lomefloxacin—Arrhythmia—Cisplatin—esophageal cancer	0.000304	0.00378	CcSEcCtD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000302	0.00683	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—ABL1—esophageal cancer	0.000297	0.00671	CbGpPWpGaD
Lomefloxacin—Dysuria—Capecitabine—esophageal cancer	0.000293	0.00364	CcSEcCtD
Lomefloxacin—Flatulence—Cisplatin—esophageal cancer	0.000292	0.00363	CcSEcCtD
Lomefloxacin—CYP1A2—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.000287	0.00647	CbGpPWpGaD
Lomefloxacin—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000286	0.00355	CcSEcCtD
Lomefloxacin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000286	0.00355	CcSEcCtD
Lomefloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.000286	0.00645	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—PSME2—esophageal cancer	0.000285	0.00644	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—PSME1—esophageal cancer	0.000285	0.00644	CbGpPWpGaD
Lomefloxacin—Muscle spasms—Cisplatin—esophageal cancer	0.000285	0.00354	CcSEcCtD
Lomefloxacin—Hyperglycaemia—Capecitabine—esophageal cancer	0.000282	0.00351	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—AJUBA—esophageal cancer	0.000281	0.00635	CbGpPWpGaD
Lomefloxacin—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000279	0.00347	CcSEcCtD
Lomefloxacin—Tremor—Cisplatin—esophageal cancer	0.000277	0.00345	CcSEcCtD
Lomefloxacin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000277	0.00344	CcSEcCtD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—esophageal cancer	0.000276	0.00623	CbGpPWpGaD
Lomefloxacin—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000275	0.00342	CcSEcCtD
Lomefloxacin—Ill-defined disorder—Cisplatin—esophageal cancer	0.000275	0.00341	CcSEcCtD
Lomefloxacin—Renal failure—Capecitabine—esophageal cancer	0.000274	0.00341	CcSEcCtD
Lomefloxacin—Myocardial infarction—Capecitabine—esophageal cancer	0.000274	0.0034	CcSEcCtD
Lomefloxacin—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000274	0.0034	CcSEcCtD
Lomefloxacin—Anaemia—Cisplatin—esophageal cancer	0.000274	0.0034	CcSEcCtD
Lomefloxacin—Stomatitis—Capecitabine—esophageal cancer	0.000272	0.00338	CcSEcCtD
Lomefloxacin—Conjunctivitis—Capecitabine—esophageal cancer	0.000271	0.00337	CcSEcCtD
Lomefloxacin—Malaise—Cisplatin—esophageal cancer	0.000267	0.00332	CcSEcCtD
Lomefloxacin—Haematuria—Capecitabine—esophageal cancer	0.000266	0.00331	CcSEcCtD
Lomefloxacin—Leukopenia—Cisplatin—esophageal cancer	0.000265	0.00329	CcSEcCtD
Lomefloxacin—Epistaxis—Capecitabine—esophageal cancer	0.000263	0.00327	CcSEcCtD
Lomefloxacin—Levofloxacin—ABCB1—esophageal cancer	0.000263	0.0823	CrCbGaD
Lomefloxacin—TOP2A—Gastric Cancer Network 2—MYC—esophageal cancer	0.000261	0.00589	CbGpPWpGaD
Lomefloxacin—Agranulocytosis—Capecitabine—esophageal cancer	0.000261	0.00324	CcSEcCtD
Lomefloxacin—Convulsion—Cisplatin—esophageal cancer	0.000256	0.00319	CcSEcCtD
Lomefloxacin—Bradycardia—Capecitabine—esophageal cancer	0.000255	0.00317	CcSEcCtD
Lomefloxacin—TOP2A—Gastric Cancer Network 2—EGFR—esophageal cancer	0.000255	0.00576	CbGpPWpGaD
Lomefloxacin—Ciprofloxacin—ABCB1—esophageal cancer	0.000254	0.0795	CrCbGaD
Lomefloxacin—Ataxia—Methotrexate—esophageal cancer	0.000254	0.00315	CcSEcCtD
Lomefloxacin—Myalgia—Cisplatin—esophageal cancer	0.000252	0.00313	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—AJUBA—esophageal cancer	0.000251	0.00568	CbGpPWpGaD
Lomefloxacin—Rhinitis—Capecitabine—esophageal cancer	0.000251	0.00312	CcSEcCtD
Lomefloxacin—Anxiety—Cisplatin—esophageal cancer	0.000251	0.00312	CcSEcCtD
Lomefloxacin—Hepatitis—Capecitabine—esophageal cancer	0.000251	0.00312	CcSEcCtD
Lomefloxacin—Discomfort—Cisplatin—esophageal cancer	0.000249	0.0031	CcSEcCtD
Lomefloxacin—Pharyngitis—Capecitabine—esophageal cancer	0.000249	0.00309	CcSEcCtD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.000243	0.00549	CbGpPWpGaD
Lomefloxacin—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000243	0.00302	CcSEcCtD
Lomefloxacin—Anaphylactic shock—Cisplatin—esophageal cancer	0.000242	0.003	CcSEcCtD
Lomefloxacin—Oedema—Cisplatin—esophageal cancer	0.000242	0.003	CcSEcCtD
Lomefloxacin—Visual impairment—Capecitabine—esophageal cancer	0.000242	0.003	CcSEcCtD
Lomefloxacin—Erythema multiforme—Capecitabine—esophageal cancer	0.000237	0.00295	CcSEcCtD
Lomefloxacin—Thrombocytopenia—Cisplatin—esophageal cancer	0.000237	0.00294	CcSEcCtD
Lomefloxacin—Tachycardia—Cisplatin—esophageal cancer	0.000236	0.00293	CcSEcCtD
Lomefloxacin—Skin disorder—Cisplatin—esophageal cancer	0.000235	0.00292	CcSEcCtD
Lomefloxacin—Tinnitus—Capecitabine—esophageal cancer	0.000234	0.00291	CcSEcCtD
Lomefloxacin—Hyperhidrosis—Cisplatin—esophageal cancer	0.000234	0.0029	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—NFE2L2—esophageal cancer	0.000233	0.00527	CbGpPWpGaD
Lomefloxacin—Flushing—Capecitabine—esophageal cancer	0.000233	0.00289	CcSEcCtD
Lomefloxacin—Eosinophilia—Methotrexate—esophageal cancer	0.000231	0.00287	CcSEcCtD
Lomefloxacin—Anorexia—Cisplatin—esophageal cancer	0.00023	0.00286	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—MLH3—esophageal cancer	0.000227	0.00513	CbGpPWpGaD
Lomefloxacin—Hypotension—Cisplatin—esophageal cancer	0.000226	0.00281	CcSEcCtD
Lomefloxacin—Chills—Capecitabine—esophageal cancer	0.000225	0.0028	CcSEcCtD
Lomefloxacin—Arrhythmia—Capecitabine—esophageal cancer	0.000224	0.00278	CcSEcCtD
Lomefloxacin—CYP1A2—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.000221	0.005	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—esophageal cancer	0.000221	0.00499	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.000221	0.00499	CbGpPWpGaD
Lomefloxacin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00022	0.00274	CcSEcCtD
Lomefloxacin—Dysuria—Methotrexate—esophageal cancer	0.000218	0.00271	CcSEcCtD
Lomefloxacin—Paraesthesia—Cisplatin—esophageal cancer	0.000217	0.0027	CcSEcCtD
Lomefloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000215	0.00486	CbGpPWpGaD
Lomefloxacin—Dyspnoea—Cisplatin—esophageal cancer	0.000215	0.00268	CcSEcCtD
Lomefloxacin—Flatulence—Capecitabine—esophageal cancer	0.000215	0.00267	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000215	0.00485	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000214	0.00484	CbGpPWpGaD
Lomefloxacin—TOP2A—Gastric Cancer Network 2—TP53—esophageal cancer	0.000214	0.00484	CbGpPWpGaD
Lomefloxacin—Dysgeusia—Capecitabine—esophageal cancer	0.000214	0.00266	CcSEcCtD
Lomefloxacin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000213	0.00265	CcSEcCtD
Lomefloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000213	0.0048	CbGpPWpGaD
Lomefloxacin—Back pain—Capecitabine—esophageal cancer	0.000211	0.00262	CcSEcCtD
Lomefloxacin—Decreased appetite—Cisplatin—esophageal cancer	0.00021	0.00261	CcSEcCtD
Lomefloxacin—Muscle spasms—Capecitabine—esophageal cancer	0.00021	0.00261	CcSEcCtD
Lomefloxacin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000206	0.00256	CcSEcCtD
Lomefloxacin—Tremor—Capecitabine—esophageal cancer	0.000204	0.00254	CcSEcCtD
Lomefloxacin—Renal failure—Methotrexate—esophageal cancer	0.000204	0.00254	CcSEcCtD
Lomefloxacin—Stomatitis—Methotrexate—esophageal cancer	0.000203	0.00252	CcSEcCtD
Lomefloxacin—Ill-defined disorder—Capecitabine—esophageal cancer	0.000202	0.00252	CcSEcCtD
Lomefloxacin—Conjunctivitis—Methotrexate—esophageal cancer	0.000202	0.00251	CcSEcCtD
Lomefloxacin—CYP1A2—Tryptophan metabolism—ALDH2—esophageal cancer	0.000202	0.00456	CbGpPWpGaD
Lomefloxacin—Anaemia—Capecitabine—esophageal cancer	0.000202	0.00251	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—CYP2A6—esophageal cancer	0.000201	0.00453	CbGpPWpGaD
Lomefloxacin—Feeling abnormal—Cisplatin—esophageal cancer	0.000199	0.00248	CcSEcCtD
Lomefloxacin—Haematuria—Methotrexate—esophageal cancer	0.000198	0.00246	CcSEcCtD
Lomefloxacin—Malaise—Capecitabine—esophageal cancer	0.000197	0.00245	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000197	0.00444	CbGpPWpGaD
Lomefloxacin—Epistaxis—Methotrexate—esophageal cancer	0.000196	0.00244	CcSEcCtD
Lomefloxacin—Vertigo—Capecitabine—esophageal cancer	0.000196	0.00244	CcSEcCtD
Lomefloxacin—Syncope—Capecitabine—esophageal cancer	0.000196	0.00243	CcSEcCtD
Lomefloxacin—TOP2A—Circadian rythm related genes—GHRL—esophageal cancer	0.000196	0.00442	CbGpPWpGaD
Lomefloxacin—Leukopenia—Capecitabine—esophageal cancer	0.000195	0.00243	CcSEcCtD
Lomefloxacin—Agranulocytosis—Methotrexate—esophageal cancer	0.000194	0.00241	CcSEcCtD
Lomefloxacin—Loss of consciousness—Capecitabine—esophageal cancer	0.000192	0.00238	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—esophageal cancer	0.000192	0.00433	CbGpPWpGaD
Lomefloxacin—Cough—Capecitabine—esophageal cancer	0.00019	0.00237	CcSEcCtD
Lomefloxacin—Hypertension—Capecitabine—esophageal cancer	0.000188	0.00234	CcSEcCtD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000188	0.00424	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000187	0.00422	CbGpPWpGaD
Lomefloxacin—Hepatitis—Methotrexate—esophageal cancer	0.000187	0.00232	CcSEcCtD
Lomefloxacin—Myalgia—Capecitabine—esophageal cancer	0.000186	0.00231	CcSEcCtD
Lomefloxacin—Chest pain—Capecitabine—esophageal cancer	0.000186	0.00231	CcSEcCtD
Lomefloxacin—Arthralgia—Capecitabine—esophageal cancer	0.000186	0.00231	CcSEcCtD
Lomefloxacin—Pharyngitis—Methotrexate—esophageal cancer	0.000185	0.0023	CcSEcCtD
Lomefloxacin—Anxiety—Capecitabine—esophageal cancer	0.000185	0.0023	CcSEcCtD
Lomefloxacin—Discomfort—Capecitabine—esophageal cancer	0.000184	0.00228	CcSEcCtD
Lomefloxacin—Dry mouth—Capecitabine—esophageal cancer	0.000182	0.00226	CcSEcCtD
Lomefloxacin—Visual impairment—Methotrexate—esophageal cancer	0.00018	0.00224	CcSEcCtD
Lomefloxacin—Confusional state—Capecitabine—esophageal cancer	0.00018	0.00223	CcSEcCtD
Lomefloxacin—Oedema—Capecitabine—esophageal cancer	0.000178	0.00221	CcSEcCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000178	0.00402	CbGpPWpGaD
Lomefloxacin—Hypersensitivity—Cisplatin—esophageal cancer	0.000178	0.00221	CcSEcCtD
Lomefloxacin—Erythema multiforme—Methotrexate—esophageal cancer	0.000176	0.00219	CcSEcCtD
Lomefloxacin—Shock—Capecitabine—esophageal cancer	0.000175	0.00218	CcSEcCtD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000175	0.00394	CbGpPWpGaD
Lomefloxacin—Thrombocytopenia—Capecitabine—esophageal cancer	0.000174	0.00217	CcSEcCtD
Lomefloxacin—Tinnitus—Methotrexate—esophageal cancer	0.000174	0.00216	CcSEcCtD
Lomefloxacin—Tachycardia—Capecitabine—esophageal cancer	0.000174	0.00216	CcSEcCtD
Lomefloxacin—Asthenia—Cisplatin—esophageal cancer	0.000173	0.00216	CcSEcCtD
Lomefloxacin—Skin disorder—Capecitabine—esophageal cancer	0.000173	0.00215	CcSEcCtD
Lomefloxacin—Hyperhidrosis—Capecitabine—esophageal cancer	0.000172	0.00214	CcSEcCtD
Lomefloxacin—Anorexia—Capecitabine—esophageal cancer	0.00017	0.00211	CcSEcCtD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000168	0.0038	CbGpPWpGaD
Lomefloxacin—Chills—Methotrexate—esophageal cancer	0.000167	0.00208	CcSEcCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000167	0.00378	CbGpPWpGaD
Lomefloxacin—Hypotension—Capecitabine—esophageal cancer	0.000166	0.00207	CcSEcCtD
Lomefloxacin—Diarrhoea—Cisplatin—esophageal cancer	0.000165	0.00206	CcSEcCtD
Lomefloxacin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000162	0.00202	CcSEcCtD
Lomefloxacin—Insomnia—Capecitabine—esophageal cancer	0.000161	0.002	CcSEcCtD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00016	0.00362	CbGpPWpGaD
Lomefloxacin—Paraesthesia—Capecitabine—esophageal cancer	0.00016	0.00199	CcSEcCtD
Lomefloxacin—Dysgeusia—Methotrexate—esophageal cancer	0.000159	0.00198	CcSEcCtD
Lomefloxacin—Dyspnoea—Capecitabine—esophageal cancer	0.000159	0.00197	CcSEcCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000159	0.00358	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000158	0.00358	CbGpPWpGaD
Lomefloxacin—Back pain—Methotrexate—esophageal cancer	0.000157	0.00195	CcSEcCtD
Lomefloxacin—Dyspepsia—Capecitabine—esophageal cancer	0.000157	0.00195	CcSEcCtD
Lomefloxacin—Decreased appetite—Capecitabine—esophageal cancer	0.000155	0.00192	CcSEcCtD
Lomefloxacin—Vomiting—Cisplatin—esophageal cancer	0.000154	0.00191	CcSEcCtD
Lomefloxacin—Fatigue—Capecitabine—esophageal cancer	0.000154	0.00191	CcSEcCtD
Lomefloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000153	0.00347	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000153	0.00347	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000153	0.00347	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.000153	0.00346	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.000153	0.00346	CbGpPWpGaD
Lomefloxacin—CYP1A2—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000153	0.00346	CbGpPWpGaD
Lomefloxacin—Rash—Cisplatin—esophageal cancer	0.000152	0.00189	CcSEcCtD
Lomefloxacin—Constipation—Capecitabine—esophageal cancer	0.000152	0.00189	CcSEcCtD
Lomefloxacin—Dermatitis—Cisplatin—esophageal cancer	0.000152	0.00189	CcSEcCtD
Lomefloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000151	0.00342	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000151	0.00342	CbGpPWpGaD
Lomefloxacin—Ill-defined disorder—Methotrexate—esophageal cancer	0.000151	0.00187	CcSEcCtD
Lomefloxacin—Anaemia—Methotrexate—esophageal cancer	0.00015	0.00187	CcSEcCtD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTO1—esophageal cancer	0.000147	0.00333	CbGpPWpGaD
Lomefloxacin—Feeling abnormal—Capecitabine—esophageal cancer	0.000147	0.00182	CcSEcCtD
Lomefloxacin—Malaise—Methotrexate—esophageal cancer	0.000146	0.00182	CcSEcCtD
Lomefloxacin—Vertigo—Methotrexate—esophageal cancer	0.000146	0.00181	CcSEcCtD
Lomefloxacin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000146	0.00181	CcSEcCtD
Lomefloxacin—Leukopenia—Methotrexate—esophageal cancer	0.000145	0.00181	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000145	0.00328	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000145	0.00328	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000145	0.00328	CbGpPWpGaD
Lomefloxacin—CYP1A2—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000144	0.00325	CbGpPWpGaD
Lomefloxacin—Nausea—Cisplatin—esophageal cancer	0.000143	0.00178	CcSEcCtD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000143	0.00323	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	0.000142	0.00322	CbGpPWpGaD
Lomefloxacin—Cough—Methotrexate—esophageal cancer	0.000142	0.00176	CcSEcCtD
Lomefloxacin—Urticaria—Capecitabine—esophageal cancer	0.000141	0.00176	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—TGFBR2—esophageal cancer	0.000141	0.00318	CbGpPWpGaD
Lomefloxacin—Abdominal pain—Capecitabine—esophageal cancer	0.000141	0.00175	CcSEcCtD
Lomefloxacin—Convulsion—Methotrexate—esophageal cancer	0.000141	0.00175	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—HMOX1—esophageal cancer	0.000139	0.00314	CbGpPWpGaD
Lomefloxacin—Myalgia—Methotrexate—esophageal cancer	0.000138	0.00172	CcSEcCtD
Lomefloxacin—Chest pain—Methotrexate—esophageal cancer	0.000138	0.00172	CcSEcCtD
Lomefloxacin—Arthralgia—Methotrexate—esophageal cancer	0.000138	0.00172	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	0.000138	0.00311	CbGpPWpGaD
Lomefloxacin—Discomfort—Methotrexate—esophageal cancer	0.000137	0.0017	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—RB1—esophageal cancer	0.000135	0.00305	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—HIST1H2BM—esophageal cancer	0.000135	0.00304	CbGpPWpGaD
Lomefloxacin—Confusional state—Methotrexate—esophageal cancer	0.000134	0.00166	CcSEcCtD
Lomefloxacin—Anaphylactic shock—Methotrexate—esophageal cancer	0.000133	0.00165	CcSEcCtD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000132	0.00299	CbGpPWpGaD
Lomefloxacin—Hypersensitivity—Capecitabine—esophageal cancer	0.000131	0.00163	CcSEcCtD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00013	0.00294	CbGpPWpGaD
Lomefloxacin—Thrombocytopenia—Methotrexate—esophageal cancer	0.00013	0.00161	CcSEcCtD
Lomefloxacin—Skin disorder—Methotrexate—esophageal cancer	0.000129	0.0016	CcSEcCtD
Lomefloxacin—Hyperhidrosis—Methotrexate—esophageal cancer	0.000128	0.00159	CcSEcCtD
Lomefloxacin—Asthenia—Capecitabine—esophageal cancer	0.000128	0.00159	CcSEcCtD
Lomefloxacin—Anorexia—Methotrexate—esophageal cancer	0.000126	0.00157	CcSEcCtD
Lomefloxacin—Pruritus—Capecitabine—esophageal cancer	0.000126	0.00157	CcSEcCtD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000124	0.00281	CbGpPWpGaD
Lomefloxacin—Hypotension—Methotrexate—esophageal cancer	0.000124	0.00154	CcSEcCtD
Lomefloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000124	0.00279	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000122	0.00276	CbGpPWpGaD
Lomefloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000122	0.00276	CbGpPWpGaD
Lomefloxacin—Diarrhoea—Capecitabine—esophageal cancer	0.000122	0.00151	CcSEcCtD
Lomefloxacin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000121	0.0015	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—HIST1H2BM—esophageal cancer	0.000121	0.00272	CbGpPWpGaD
Lomefloxacin—Insomnia—Methotrexate—esophageal cancer	0.00012	0.00149	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.000119	0.00269	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	0.000119	0.00269	CbGpPWpGaD
Lomefloxacin—Paraesthesia—Methotrexate—esophageal cancer	0.000119	0.00148	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	0.000119	0.00268	CbGpPWpGaD
Lomefloxacin—Dyspnoea—Methotrexate—esophageal cancer	0.000118	0.00147	CcSEcCtD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000118	0.00266	CbGpPWpGaD
Lomefloxacin—Somnolence—Methotrexate—esophageal cancer	0.000118	0.00147	CcSEcCtD
Lomefloxacin—Dizziness—Capecitabine—esophageal cancer	0.000118	0.00146	CcSEcCtD
Lomefloxacin—Dyspepsia—Methotrexate—esophageal cancer	0.000117	0.00145	CcSEcCtD
Lomefloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000116	0.00263	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000116	0.00262	CbGpPWpGaD
Lomefloxacin—Decreased appetite—Methotrexate—esophageal cancer	0.000115	0.00143	CcSEcCtD
Lomefloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000115	0.00259	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.000114	0.00258	CbGpPWpGaD
Lomefloxacin—Fatigue—Methotrexate—esophageal cancer	0.000114	0.00142	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	0.000114	0.00258	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.000114	0.00257	CbGpPWpGaD
Lomefloxacin—Vomiting—Capecitabine—esophageal cancer	0.000113	0.00141	CcSEcCtD
Lomefloxacin—Rash—Capecitabine—esophageal cancer	0.000112	0.0014	CcSEcCtD
Lomefloxacin—Dermatitis—Capecitabine—esophageal cancer	0.000112	0.00139	CcSEcCtD
Lomefloxacin—Headache—Capecitabine—esophageal cancer	0.000112	0.00139	CcSEcCtD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000111	0.0025	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00011	0.00248	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—NOS2—esophageal cancer	0.00011	0.00248	CbGpPWpGaD
Lomefloxacin—Feeling abnormal—Methotrexate—esophageal cancer	0.000109	0.00136	CcSEcCtD
Lomefloxacin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000108	0.00135	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—MAD2L1—esophageal cancer	0.000106	0.0024	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000106	0.0024	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000106	0.0024	CbGpPWpGaD
Lomefloxacin—Nausea—Capecitabine—esophageal cancer	0.000106	0.00132	CcSEcCtD
Lomefloxacin—Urticaria—Methotrexate—esophageal cancer	0.000105	0.00131	CcSEcCtD
Lomefloxacin—Abdominal pain—Methotrexate—esophageal cancer	0.000105	0.0013	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—PSME1—esophageal cancer	0.000105	0.00236	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—PSME2—esophageal cancer	0.000105	0.00236	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000103	0.00233	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000103	0.00232	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.0001	0.00227	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CCND1—esophageal cancer	0.0001	0.00226	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—GNG7—esophageal cancer	9.98e-05	0.00225	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	9.98e-05	0.00225	CbGpPWpGaD
Lomefloxacin—Hypersensitivity—Methotrexate—esophageal cancer	9.77e-05	0.00121	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	9.69e-05	0.00219	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—BUB1B—esophageal cancer	9.52e-05	0.00215	CbGpPWpGaD
Lomefloxacin—Asthenia—Methotrexate—esophageal cancer	9.51e-05	0.00118	CcSEcCtD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	9.43e-05	0.00213	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	9.38e-05	0.00212	CbGpPWpGaD
Lomefloxacin—Pruritus—Methotrexate—esophageal cancer	9.38e-05	0.00117	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—PSME1—esophageal cancer	9.35e-05	0.00211	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—PSME2—esophageal cancer	9.35e-05	0.00211	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	9.28e-05	0.00209	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	9.15e-05	0.00207	CbGpPWpGaD
Lomefloxacin—Diarrhoea—Methotrexate—esophageal cancer	9.07e-05	0.00113	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	8.84e-05	0.002	CbGpPWpGaD
Lomefloxacin—Dizziness—Methotrexate—esophageal cancer	8.77e-05	0.00109	CcSEcCtD
Lomefloxacin—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	8.62e-05	0.00195	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	8.59e-05	0.00194	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—BUB1B—esophageal cancer	8.51e-05	0.00192	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	8.51e-05	0.00192	CbGpPWpGaD
Lomefloxacin—Vomiting—Methotrexate—esophageal cancer	8.43e-05	0.00105	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	8.4e-05	0.0019	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	8.39e-05	0.00189	CbGpPWpGaD
Lomefloxacin—Rash—Methotrexate—esophageal cancer	8.36e-05	0.00104	CcSEcCtD
Lomefloxacin—Dermatitis—Methotrexate—esophageal cancer	8.35e-05	0.00104	CcSEcCtD
Lomefloxacin—Headache—Methotrexate—esophageal cancer	8.3e-05	0.00103	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—CHEK2—esophageal cancer	8.09e-05	0.00183	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—MYC—esophageal cancer	8.04e-05	0.00181	CbGpPWpGaD
Lomefloxacin—Nausea—Methotrexate—esophageal cancer	7.87e-05	0.000979	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	7.59e-05	0.00171	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	7.34e-05	0.00166	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—GNG7—esophageal cancer	7.3e-05	0.00165	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	7.03e-05	0.00159	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	6.99e-05	0.00158	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	6.9e-05	0.00156	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—EP300—esophageal cancer	6.71e-05	0.00151	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	6.69e-05	0.00151	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	6.61e-05	0.00149	CbGpPWpGaD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	6.45e-05	0.00146	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	6.27e-05	0.00142	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	6.09e-05	0.00137	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—HMOX1—esophageal cancer	6.08e-05	0.00137	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	6.03e-05	0.00136	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	5.95e-05	0.00134	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—ABCB1—esophageal cancer	5.84e-05	0.00132	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	5.74e-05	0.0013	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	5.74e-05	0.0013	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	5.33e-05	0.0012	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	5.25e-05	0.00119	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	5.17e-05	0.00117	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	5.14e-05	0.00116	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	5.01e-05	0.00113	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	5e-05	0.00113	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	5e-05	0.00113	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—RB1—esophageal cancer	4.95e-05	0.00112	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	4.94e-05	0.00112	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	4.89e-05	0.0011	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	4.89e-05	0.0011	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—TP53—esophageal cancer	4.8e-05	0.00108	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.45e-05	0.001	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—RB1—esophageal cancer	4.42e-05	0.000999	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	4.35e-05	0.000982	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	4.27e-05	0.000964	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.9e-05	0.000881	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CDKN2A—esophageal cancer	3.89e-05	0.000878	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CCND1—esophageal cancer	3.67e-05	0.00083	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	3.55e-05	0.000803	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	3.47e-05	0.000784	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—EP300—esophageal cancer	3.38e-05	0.000764	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CCND1—esophageal cancer	3.29e-05	0.000742	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CDKN1A—esophageal cancer	3.18e-05	0.000718	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	3.03e-05	0.000684	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—EP300—esophageal cancer	3.02e-05	0.000683	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—MYC—esophageal cancer	2.95e-05	0.000666	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.85e-05	0.000644	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—SLC52A3—esophageal cancer	2.69e-05	0.000608	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—BLVRB—esophageal cancer	2.69e-05	0.000608	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—MYC—esophageal cancer	2.64e-05	0.000595	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	2.41e-05	0.000543	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CA1—esophageal cancer	2.29e-05	0.000517	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—SLC10A2—esophageal cancer	2.29e-05	0.000517	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—TP53—esophageal cancer	2.16e-05	0.000489	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CA2—esophageal cancer	2.09e-05	0.000473	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.05e-05	0.000462	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ADH7—esophageal cancer	1.95e-05	0.000439	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PLCE1—esophageal cancer	1.95e-05	0.000439	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.92e-05	0.000434	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.71e-05	0.000385	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—TYMP—esophageal cancer	1.63e-05	0.000368	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.59e-05	0.000358	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.55e-05	0.000349	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.47e-05	0.000333	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—TPI1—esophageal cancer	1.47e-05	0.000333	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.41e-05	0.000319	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.36e-05	0.000307	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.35e-05	0.000305	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GNG7—esophageal cancer	1.28e-05	0.00029	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.2e-05	0.000272	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.14e-05	0.000258	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.13e-05	0.000255	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.13e-05	0.000254	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ENO1—esophageal cancer	1.07e-05	0.000242	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.07e-05	0.000242	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PSME2—esophageal cancer	1.06e-05	0.000238	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PSME1—esophageal cancer	1.06e-05	0.000238	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	9.22e-06	0.000208	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CYP1B1—esophageal cancer	9.11e-06	0.000206	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CYP19A1—esophageal cancer	8.57e-06	0.000193	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—HMOX1—esophageal cancer	7.82e-06	0.000177	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.67e-06	0.000173	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ABCB1—esophageal cancer	7.5e-06	0.000169	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.67e-06	0.000128	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CREBBP—esophageal cancer	5.01e-06	0.000113	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—NOS3—esophageal cancer	4.49e-06	0.000101	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PTGS2—esophageal cancer	4.11e-06	9.27e-05	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—EP300—esophageal cancer	3.42e-06	7.71e-05	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PIK3CA—esophageal cancer	2.53e-06	5.71e-05	CbGpPWpGaD
